Cocrystal Pharma Reports Favorable Results From Single-Ascending Dose Cohorts of Phase 1 Study With Cdi-988, Its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
Cocrystal Pharma宣佈CDI-988口服泛病毒諾如病毒/冠狀病毒蛋白酶抑制劑一期研究單次遞增劑量隊列的結果良好。
Cocrystal Pharma Reports Favorable Results From Single-Ascending Dose Cohorts of Phase 1 Study With Cdi-988, Its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
Cocrystal Pharma宣佈CDI-988口服泛病毒諾如病毒/冠狀病毒蛋白酶抑制劑一期研究單次遞增劑量隊列的結果良好。
譯文內容由第三人軟體翻譯。